Revance, based in Silicon Valley, has been around since 1999 and is developing an experimental product for frown lines, forehead lines, and crow's feet that would compete with Botox. The product, DAXI, is in late-stage development, and the company plans to submit it for FDA approval this fall.
Revance is also working with the drugmaker Mylan to develop a copycat, "biosimilar" version of Botox. The biotech also has experimental medicines in the works for a neurological movement disorder, migraines, the degenerative musculoskeletal condition plantar fasciitis, and more.
On Tuesday's conference call with investors, AbbVie CEO Rick Gonzalez questioned whether another company would be able to make a biosimilar copycat of Botox. But "the jury is still out in our view," said the Stifel analyst team.
Revance has a market value of $550 million, and the stock jumped 5% yesterday after the AbbVie-Allergan deal was announced.
The Stifel team rates Revance a "buy," with a price target of $12.14 a share.
TherapeuticsMD was founded in 2008 and is headquartered in Florida. It's focused on medicines for women's health, like treatments for menopause symptoms.
AbbVie's interest in women's health "bodes well for others in the space that could broaden the portfolio meaningfully," the Stifel analysts said, like TherapeuticsMD.
Other companies in women's health, like Myovant Sciences and Obseva, by contrast, compete with AbbVie drugs like the endometriosis drug Orilissa, they said.
The drugmaker has a market cap of about $610 million.
Founded in 2005 and headquartered in North Carolina, Aerie focuses on the development and commercialization of treatments for glaucoma, retinal disease and other eye conditions.
It already has two approved drugs, Rhopressa and Rocklatan for high eye pressure. Aerie is also developing an experimental implant for diabetic macular edema, which is currently being tested out in early and mid-stage research trials.
While Stifel analysts don't believe that eye care is of as much interest as women's health to AbbVie, the drugmaker did call Allergan "a leader in glaucoma and dry eye," the Stifel team noted.
"We see AERI, with on-market Rhopressa/Rocklatan and a self-fueling pipeline, as an interesting target to maintain that leadership," they said. The analysts rate Aerie "buy" with a $30.32 price target.
Aerie has a market cap of about $1.3 billion.
Founded in 2009 and based in Massachusetts, Kala Pharmaceuticals was named after a famous hiking trail in Hawaii known for its views.
The drugmaker is focused on eye disease, with its furthest-along product, KPT-121, in late development for the short-term treatment of dry eye.
Because that drug is so advanced, Kala could also be of interest to a company like AbbVie, the Stifel team said.
Kala has a market value of about $190 million.
I spent 2 weeks in India. A highlight was visiting a small mountain town so beautiful it didn't seem real. 
I quit McKinsey after 1.5 years. I was making over $200k but my mental health was shattered.
Some Tesla factory workers realized they were laid off when security scanned their badges and sent them back on shuttles, sources say
Stock markets stage strong rebound after 4 days of slump; Sensex rallies 599 pts
Sustainable Transportation Alternatives
10 Foods you should avoid eating when in stress
Next Story